Stockscreener 앱 받기
4.385
5.04%
0.215
전일 마감가:
$4.17
열려 있는:
$4.13
하루 거래량:
2.64M
Relative Volume:
0.44
시가총액:
$1.31B
수익:
$38.03M
순이익/손실:
$-146.40M
주가수익비율:
-8.4327
EPS:
-0.52
순현금흐름:
$-121.38M
1주 성능:
-2.67%
1개월 성능:
-14.95%
6개월 성능:
+44.55%
1년 성능:
+65.91%
1일 변동 폭
$4.13
$4.3875
1주일 범위
$4.01
$4.81
52주 변동 폭
$1.8906
$5.82
앱셀레라바이오로직스 Stock (ABCL) Company Profile
명칭
Abcellera Biologics Inc
전화
(604) 559-9005
주소
150 W 4TH AVENUE, VANCOUVER
ABCL을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ABCL
Abcellera Biologics Inc
|
4.3851 | 1.40B | 38.03M | -146.40M | -121.38M | -0.52 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.31 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
601.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.78 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
662.54 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
311.66 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
앱셀레라바이오로직스 Stock (ABCL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-07 | 재개 | Leerink Partners | Outperform |
| 2024-08-20 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2024-02-22 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2023-12-05 | 개시 | KeyBanc Capital Markets | Overweight |
| 2023-11-06 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2023-10-13 | 재개 | Piper Sandler | Overweight |
| 2023-02-28 | 개시 | Cowen | Outperform |
| 2022-12-15 | 개시 | Goldman | Buy |
| 2022-11-16 | 개시 | Truist | Buy |
| 2021-12-21 | 개시 | The Benchmark Company | Buy |
| 2021-11-19 | 개시 | Piper Sandler | Overweight |
| 2021-01-05 | 개시 | BMO Capital Markets | Outperform |
| 2021-01-05 | 개시 | Berenberg | Buy |
| 2021-01-05 | 개시 | Credit Suisse | Outperform |
| 2021-01-05 | 개시 | SVB Leerink | Outperform |
| 2021-01-05 | 개시 | Stifel | Buy |
모두보기
앱셀레라바이오로직스 주식(ABCL)의 최신 뉴스
What Technical Tools Say About AbCellera Biologics Inc. RecoveryMarket Growth Summary & AI Powered Trade Plan Recommendations - newsyoung.net
ABCL.O Dives 6.75%—No News, No Signals—What’s Behind the Sharp Drop? - AInvest
AbCellera Biologics Inc. stock trend outlook and recovery pathEarnings Recap Report & Expert Approved Momentum Trade Ideas - Newser
AbCellera Biologics (ABCL) Advances Proprietary Pipeline with Promising Phase 1 Trial Results - Insider Monkey
Best data tools to analyze AbCellera Biologics Inc. stockQuarterly Portfolio Report & Real-Time Market Sentiment Reports - Newser
AbCellera Biologics Inc. stock chart pattern explained2025 Market Overview & Precise Swing Trade Entry Alerts - Newser
Why AbCellera Biologics Inc. stock attracts strong analyst attentionJuly 2025 Final Week & Expert Approved Trade Ideas - Newser
Smart tools for monitoring AbCellera Biologics Inc.’s price action2025 Top Gainers & Verified Entry Point Signals - Newser
How to build a dashboard for AbCellera Biologics Inc. stockJuly 2025 Rallies & AI Powered Market Entry Strategies - Newser
AbCellera Biologics Inc. stock outlook for YEARJuly 2025 Market Mood & AI Based Buy/Sell Signal Reports - Newser
Price momentum metrics for AbCellera Biologics Inc. explainedEarnings Overview Report & Expert Verified Movement Alerts - Newser
Ranking AbCellera Biologics Inc. among high performing stocks via tools2025 Trading Recap & Risk Controlled Swing Alerts - Newser
12 Best Healthcare Stocks to Buy Under $30 - Insider Monkey
AbCellera Biologics (NASDAQ:ABCL) Raised to “Hold” at Wall Street Zen - Defense World
Detecting price anomalies in AbCellera Biologics Inc. with AI2025 Year in Review & Free High Accuracy Swing Entry Alerts - Newser
How AbCellera Biologics Inc. stock performs during market volatilityJuly 2025 Pullbacks & Stepwise Trade Signal Implementation - Newser
AbCellera Biologics Earnings Call: Clinical Progress and Financial Insights - MSN
AbCellera Biologics Inc. Bounces Off Moving Average SupportWeekly Risk Report & Consistent Profit Trading Strategies - sundaytimes.kr
Prelude Cuts Q2 Losses and Costs 13% - The Motley Fool
AbCellera Biologics stock rating maintained at Hold by Benchmark - Investing.com
AbCellera to Participate at Upcoming Investor Conferences in September 2025 - BioSpace
AbCellera Biologics (ABCL) Q2 2025 Earnings Call Transcript - AOL.com
AbCellera to Present at Upcoming Investor Conferences in September - AInvest
AbCellera to Participate at Upcoming Investor Conferences in September - Business Wire
Penny Stocks to Watch for Growth: KORU Medical Systems, AbCellera Biologics, and Top 10 US Penny Stocks - AInvest
Industry Analysts Just Made A Huge Upgrade To Their AbCellera Biologics Inc. (NASDAQ:ABCL) Revenue Forecasts - uk.finance.yahoo.com
Multi factor analysis applied to AbCellera Biologics Inc.Free AI Forecast for Trending Stocks - Newser
How does AbCellera Biologics Inc. score in quality rankingsFree Market Open Stock Picks - newsyoung.net
AbCellera's Q2 2025 Earnings Call: Unpacking Contradictions in Regulatory Focus, Dosing Strategies, and Market Expansion - AInvest
Will AbCellera Biologics Inc. benefit from seasonalityRocket Stock Alert Service - mustnews.co.kr
AbCellera Biologics Advances Clinical Trials and Revenue Growth - TipRanks
AbCellera reports Q2 EPS (12c), consensus (16c) - MSN
AbCellera Biologics Inc. (ABCL) Reports Q2 Loss, Beats Revenue Estimates - MSN
AbCellera signals clinical-stage transition with first patient dosing for ABCL635 and targets mid-2026 data milestone - MSN
AbCellera Biologics Inc. (NASDAQ:ABCL) Q2 2025 Earnings Call Transcript - Insider Monkey
AbCellera Biologics (NASDAQ:ABCL) Shares Gap Up Following Strong Earnings - Defense World
AbCellera Biologics 2025 Q2 Earnings Net Loss Narrows Slightly - AInvest
AbCellera Biologics Reports Q2 2025 Financial Results - The Globe and Mail
AbCellera Biologics Soars 19.34% on Q2 Revenue Surge - AInvest
AbCellera Biologics Inc. shares rise 15.80% premarket after reporting Q2 revenue beat estimates and beginning Phase 1 clinical trial for ABCL635. - AInvest
AbCellera Biologics Inc (ABCL) Q2 2025 Earnings Call Highlights: Revenue Surge and Clinical ... - Yahoo Finance
AbCellera Biologics Inc (ABCL) Q2 2025 Earnings Call Highlights: Revenue Surge and Clinical ... By GuruFocus - Investing.com Canada
AbCellera Reports Q2 2025 Business Results & First Participants Dosed in a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms - BioSpace
Decoding AbCellera Biologics Inc (ABCL): A Strategic SWOT Insigh - GuruFocus
AbCellera Biologics: Promising Pipeline and Strategic Focus Justify Buy Rating - TipRanks
Canadian biotech firm AbCellera Q2 revenue beats estimates - MarketScreener
AbCellera soars as revenue more than doubles estimates By Investing.com - Investing.com Australia
AbCellera soars as revenue more than doubles estimates - Investing.com
Abcellera Biologics earnings beat by $0.02, revenue topped estimates - Investing.com Canada
AbCellera Biologics: A Turning Point in Biotech's Antibody Revolution - AInvest
AbCellera begins dosing in phase 1 trial for menopause treatment By Investing.com - Investing.com Nigeria
앱셀레라바이오로직스 (ABCL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.18%
0.54%
자본화:
|
볼륨(24시간):